Vorinostat Completed Phase 1 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00111813Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
NCT00858234Phase I Study of MK0683 in Combination With Bortezomib in Multiple Myeloma Patients (0683-098)